Both TALENs and CRISPR/Cas9 directly target the HBB IVS2-654 (C > T) mutation in β-thalassemiaderived iPSCs

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Xu, Peng ^a   Tong, Ying ^a   Liu, Xiu Zhen ^a   Wang, Ting Ting ^a   Cheng, Li ^a,b   Wang, Bo Yu ^a   Lv, Xiang ^a   Huang, Yue ^a,b   Liu, De Pei ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN BETA CHAIN;

BETA THALASSEMIA; CELL DIFFERENTIATION; CELL SELF-RENEWAL; CHEMISTRY; CRISPR CAS SYSTEM; CYTOLOGY; GENE LOCUS; GENE ORDER; GENE TARGETING; GENETIC TRANSCRIPTION; GENETICS; HOMOLOGOUS RECOMBINATION; HUMAN; INDUCED PLURIPOTENT STEM CELL; INTRON; KARYOTYPE; METABOLISM; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; SEQUENCE ALIGNMENT;

BASE SEQUENCE; BETA-GLOBINS; BETA-THALASSEMIA; CELL DIFFERENTIATION; CELL SELF RENEWAL; CRISPR-CAS SYSTEMS; GENE ORDER; GENE TARGETING; GENETIC LOCI; HOMOLOGOUS RECOMBINATION; HUMANS; INDUCED PLURIPOTENT STEM CELLS; INTRONS; KARYOTYPE; MOLECULAR SEQUENCE DATA; MUTATION; SEQUENCE ALIGNMENT; TRANSCRIPTION, GENETIC;

EID: 84937019827     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep12065     Document Type: Article

References (49)

1. Rund, D. & Rachmilewitz, E. Beta-thalassemia. N Engl J Med 353, 1135-1146 (2005).
2. Ma, N. et al. Transcription activator-like effector nuclease (TALEN)-mediated gene correction in integration-free beta-thalassemia induced pluripotent stem cells. J Biol Chem 288, 34671-34679 (2013).
3. Weatherall, D. J. Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. Nat Rev Genet 2, 245-255 (2001).
4. Marziali, M., Isgro, A., Gaziev, J. & Lucarelli, G. Hematopoietic stem cell transplantation in thalassemia and sickle cell disease. Unicenter experience in a multi-ethnic population. Mediterr J Hematol Infect Dis 1, e2009027 (2009).
5. Libani, I. V. et al. Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalassemia. Blood 112, 875-885 (2008).
6. Cao, A. & Kan, Y. W. The prevention of thalassemia. Cold Spring Harb Perspect Med 3, a011775 (2013).
7. Kazazian, H. H., Jr. & Boehm, C. D. Molecular basis and prenatal diagnosis of beta-thalassemia. Blood 72, 1107-1116 (1988).
8. Cheng, T. C. et al. beta-Thalassemia in Chinese: use of in vivo RNA analysis and oligonucleotide hybridization in systematic characterization of molecular defects. Proc Natl Acad Sci USA 81, 2821-2825 (1984).
9. Zhang, J. Z. et al. Molecular basis of beta thalassemia in south China. Strategy for DNA analysis. Hum Genet 78, 37-40 (1988).
10. Lucarelli, G. et al. Bone marrow transplantation in adult thalassemic patients. Blood 93, 1164-1167 (1999).
11. Cavazzana-Calvo, M. et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 467, 318-322 (2010).
12. Pawliuk, R. et al. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science 294, 2368-2371 (2001).
13. Wang, Y., Jiang, Y., Liu, S., Sun, X. & Gao, S. Generation of induced pluripotent stem cells from human beta-thalassemia fibroblast cells. Cell Res 19, 1120-1123 (2009).
14. Wang, Y. et al. Genetic correction of beta-thalassemia patient-specific iPS cells and its use in improving hemoglobin production in irradiated SCID mice. Cell Res 22, 637-648 (2012).
15. Hockemeyer, D. et al. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat Biotechnol 27, 851-857 (2009).
16. Hockemeyer, D. et al. Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol 29, 731-734 (2011).
17. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823 (2013).
18. Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823-826 (2013).
19. Chang, C. J. & Bouhassira, E. E. Zinc-finger nuclease-mediated correction of alpha-thalassemia in iPS cells. Blood 120, 3906- 3914 (2012).
20. Ramirez, C. L. et al. Unexpected failure rates for modular assembly of engineered zinc fingers. Nat Methods 5, 374-375 (2008).
21. Xie, F. et al. Seamless gene correction of beta-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac. Genome Res 24, 1526-1533 (2014).
22. Song, B. et al. Improved Hematopoietic Differentiation Efficiency of Gene-Corrected Beta-Thalassemia Induced Pluripotent Stem Cells by CRISPR/Cas9 System. Stem Cells Dev 24, 1053-1065 (2015).
23. Chen, Y. T. & Bradley, A. A new positive/negative selectable marker, puDeltatk, for use in embryonic stem cells. Genesis 28, 31-35 (2000).
24. Doyle, E. L. et al. TAL Effector-Nucleotide Targeter (TALE-NT) 2.0: tools for TAL effector design and target prediction. Nucleic Acids Res 40, W117-W122 (2012).
25. Bae, S., Park, J. & Kim, J. S. Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNAguided endonucleases. Bioinformatics 30, 1473-1475 (2014).
26. Thomas, K. R. & Capecchi, M. R. Introduction of homologous DNA sequences into mammalian cells induces mutations in the cognate gene. Nature 324, 34-38 (1986).
27. Smithies, O., Gregg, R. G., Boggs, S. S., Koralewski, M. A. & Kucherlapati, R. S. Insertion of DNA sequences into the human chromosomal beta-globin locus by homologous recombination. Nature 317, 230-234 (1985).
28. Robertson, E., Bradley, A., Kuehn, M. & Evans, M. Germ-line transmission of genes introduced into cultured pluripotential cells by retroviral vector. Nature 323, 445-448 (1986).
29. Maeder, M. L. et al. Rapid "open-source" engineering of customized zinc-finger nucleases for highly efficient gene modification. Mol Cell 31, 294-301 (2008).
30. Pruett-Miller, S. M., Connelly, J. P., Maeder, M. L., Joung, J. K. & Porteus, M. H. Comparison of zinc finger nucleases for use in gene targeting in mammalian cells. Mol Ther 16, 707-717 (2008).
31. Kim, Y. et al. A library of TAL effector nucleases spanning the human genome. Nat Biotechnol 31, 251-258 (2013).
32. Smith, C. et al. Efficient and allele-specific genome editing of disease loci in human iPSCs. Mol Ther 23, 570-577 (2015).
33. Cradick, T. J., Fine, E. J., Antico, C. J. & Bao, G. CRISPR/Cas9 systems targeting beta-globin and CCR5 genes have substantial off-target activity. Nucleic Acids Res 41, 9584-9592 (2013).
34. Ding, Q. et al. Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs. Cell Stem Cell 12, 393-394 (2013).
35. Ran, F. A. et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154, 1380-1389 (2013).
36. Maresca, M., Lin, V. G., Guo, N. & Yang, Y. Obligate ligation-gated recombination (ObLiGaRe): custom-designed nucleasemediated targeted integration through nonhomologous end joining. Genome Res 23, 539-546 (2013).
37. Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816-821 (2012).
38. Davis, L. & Maizels, N. Homology-directed repair of DNA nicks via pathways distinct from canonical double-strand break repair. Proc Natl Acad Sci USA 111, E924-E932 (2014).
39. Mali, P. et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol 31, 833-838 (2013).
40. Frock, R. L. et al. Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases. Nat Biotechnol (2014).
41. Kuscu, C., Arslan, S., Singh, R., Thorpe, J. & Adli, M. Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease. Nat Biotechnol 32, 677-683 (2014).
42. Wang, X. et al. Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors. Nat Biotechnol (2015).
43. Smith, C. et al. Whole-genome sequencing analysis reveals high specificity of CRISPR/Cas9 and TALEN-based genome editing in human iPSCs. Cell Stem Cell 15, 12-13 (2014).
44. Veres, A. et al. Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing. Cell Stem Cell 15, 27-30 (2014).
45. Cho, S. W. et al. Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome Res 24, 132-141 (2014).
46. Shen, B. et al. Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. Nat Methods 11, 399-402 (2014).
47. Wang, X. et al. Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors. Nat Biotechnol 33, 175-178 (2015).
48. Yusa, K. et al. Targeted gene correction of alpha1-antitrypsin deficiency in induced pluripotent stem cells. Nature 478, 391-394 (2011).
49. Sun, N. & Zhao, H. Seamless correction of the sickle cell disease mutation of the HBB gene in human induced pluripotent stem cells using TALENs. Biotechnol Bioeng 111, 1048-1053 (2014).